(CURE) Direxion Daily Healthcare - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US25459Y8764 • Trading--Leveraged Equity

CURE: Pharmaceuticals, Biotechnology, Medical Equipment, Healthcare Providers

The Direxion Daily Healthcare Bull 3X Shares (NYSE ARCA:CURE) is a leveraged ETF designed to provide 3X daily returns relative to the performance of its underlying index, which tracks domestic healthcare companies. The fund allocates at least 80% of its net assets to financial instruments delivering 3X exposure to the index. The index spans key healthcare subsectors, including pharmaceuticals, healthcare equipment, biotechnology, healthcare providers, and life sciences. As a non-diversified fund, it can concentrate investments in a smaller range of securities. For more information, visit http://www.direxionfunds.com.

3-Month Forecast: Based on the technical and fundamental data, CURE is expected to trade within a range of $110-$120 over the next three months. The funds price of $115.25 is currently above its 20-day SMA ($110.06) and 50-day SMA ($103.15) but slightly below its 200-day SMA ($116.71), suggesting near-term bullish momentum with potential resistance near $117. The ATR of 3.61 indicates moderate daily volatility, while the AUM of $177.65M reflects sufficient liquidity to support its trading strategy.

Ticker Symbol: CURE Exchange: NYSE ARCA Type: ETF Country Origin: USA ETF Category: Trading--Leveraged Equity Average Volume 20d: 50079 Last Price: 115.25 SMA 20: 110.06 SMA 50: 103.15 SMA 200: 116.71 ATR: 3.61 AUM: 177.65M USD

Additional Sources for CURE ETF

CURE ETF Overview

Market Cap in USD 177m
Category Trading--Leveraged Equity
TER 0.96%
IPO / Inception 2011-06-15

CURE ETF Ratings

Growth 5y 50.4%
Fundamental -
Dividend 43.5%
Rel. Strength Industry -21.1
Analysts -
Fair Price Momentum 100.52 USD
Fair Price DCF -

CURE Dividends

Dividend Yield 12m 0.98%
Yield on Cost 5y 3.37%
Annual Growth 5y 52.17%
Payout Consistency 40.2%

CURE Growth Ratios

Growth Correlation 3m 77.3%
Growth Correlation 12m -29.6%
Growth Correlation 5y 55.8%
CAGR 5y 26.66%
CAGR/Max DD 5y 0.57
Sharpe Ratio 12m -0.49
Alpha -25.31
Beta 1.30
Volatility 38.74%
Current Volume 21.5k
Average Volume 20d 44.4k
What is the price of CURE stocks?
As of March 15, 2025, the stock is trading at USD 104.31 with a total of 21,462 shares traded.
Over the past week, the price has changed by -8.63%, over one month by -0.91%, over three months by +9.72% and over the past year by -12.64%.
Is Direxion Daily Healthcare a good stock to buy?
Partly, yes. Based on ValueRay Analyses, Direxion Daily Healthcare (NYSE ARCA:CURE) is currently (March 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 50.40 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CURE as of March 2025 is 100.52. This means that CURE is currently overvalued and has a potential downside of -3.63%.
Is CURE a buy, sell or hold?
Direxion Daily Healthcare has no consensus analysts rating.
What are the forecast for CURE stock price target?
According to ValueRays Forecast Model, CURE Direxion Daily Healthcare will be worth about 116.5 in March 2026. The stock is currently trading at 104.31. This means that the stock has a potential upside of +11.66%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 116.5 11.7%